Evidence map›Paper›PMID 32214382›Full record

Trial reportPLoS pathogens2020

Cervicovaginal microbiome and natural history of HPV in a longitudinal study.

Mykhaylo Usyk, Christine P Zolnik, Philip E Castle, Carolina Porras, Rolando Herrero, Ana Gradissimo, Paula Gonzalez, Mahboobeh Safaeian, Mark Schiffman, Robert D Burk and 1 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00128661 (A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia), which is not on this map. Cited by 181 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
181citing papers in PubMed, 3 pooled it
30.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00128661 phase3completednot on this map

A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica.

TypeinterventionalSponsorGlaxoSmithKlineRan2004 to 2010Enrolled7,466ConditionsCervical Cancer, Precancerous ConditionArmshuman papillomavirus 16/18 L1 virus-like particle/AS04 vaccine, hepatitis A inactivated virus vaccine
3 · Its place in the literature

Who cites it

181 citing papers in PubMed, 3 syntheses or guidelines pooled it, 314 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

121 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Mykhaylo UsykDepartment of Pediatrics (Genetic Medicine), Albert Einstein College of Medicine, Bronx, New York, United States of America.
Christine P ZolnikDepartment of Pediatrics (Genetic Medicine), Albert Einstein College of Medicine, Bronx, New York, United States of America.ORCID 0000-0002-6429-8112
Philip E CastleDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, United States of America.ORCID 0000-0003-1082-6554
Carolina PorrasAgencia Costarricense de Investigaciones Biomédicas (ACIB), formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica.
Rolando HerreroPrevention and Implementation Group, International Agency for Research on Cancer, Lyon, France.
Ana GradissimoDepartment of Pediatrics (Genetic Medicine), Albert Einstein College of Medicine, Bronx, New York, United States of America.ORCID 0000-0003-1621-6693
Paula GonzalezAgencia Costarricense de Investigaciones Biomédicas (ACIB), formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica.
Mahboobeh SafaeianRoche Molecular Diagnostics, Pleasanton, California, United States of America.
Mark SchiffmanDivision of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, NIH, Bethesda, Maryland, United States of America.
Robert D BurkDepartment of Pediatrics (Genetic Medicine), Albert Einstein College of Medicine, Bronx, New York, United States of America.ORCID 0000-0002-8376-8458
Costa Rica HPV Vaccine Trial (CVT) Group
Albert Einstein College of Medicine · USInstituto Costarricense de Investigación y Enseñanza en Nutrición y Salud · CRCentre international de recherche sur le cancer · FRNational Cancer Institute · USRoche (United States) · US

Funding

HPV TYPE 16 VACCINE TRIAL IN COSTA RICAN01CP11005 · NCI · FUNDACION INCIENSA · PI HERRERO, ROLANDO · 2007 to 2012
$17.9M
PERSISTENT HUMAN PAPILLOMAVIRUS IN WOMEN AT RISK FOR CERVIX CANCERU01CA078527 · NCI · YESHIVA UNIVERSITY · PI BURK, ROBERT D · 2003 to 2018
$8.6M
NCI NIH HHS N01 CP011005NCI NIH HHS N01CP11005NCI NIH HHS U01 CA078527World Health Organization 001
6 · The paper itself

Abstract

backgroundHuman papillomavirus (HPV) infection is one of the most common sexually transmitted infections. However, only a small percentage of high-risk (HR) HPV infections progress to cervical precancer and cancer. In this study, we investigated the role of the cervicovaginal microbiome (CVM) in the natural history of HR-HPV.

methodsThis study was nested within the placebo arm of the Costa Rica HPV Vaccine Trial that included women aged 18-25 years of age. Cervical samples from two visits of women with an incident HR-HPV infection (n = 273 women) were used to evaluate the prospective role of the CVM on the natural history of HR-HPV. We focus specifically on infection clearance, persistence, and progression to cervical intraepithelial neoplasia grade 2 and 3 (CIN2+). The CVM was characterized by amplification and sequencing the bacterial 16S V4 rRNA gene region and the fungal ITS1 region using an Illumina MiSeq platform. OTU clustering was performed using QIIME2. Functional groups were imputed using PICRUSt and statistical analyses were performed using R.

resultsAt Visit 1 (V1) abundance of Lactobacillus iners was associated with clearance of incident HR-HPV infections (Linear Discriminant Analysis (LDA)>4.0), whereas V1 Gardnerella was the dominant biomarker for HR-HPV progression (LDA>4.0). At visit 2 (V2), increased microbial Shannon diversity was significantly associated with progression to CIN2+ (p = 0.027). Multivariate mediation analysis revealed that the positive association of V1 Gardnerella with CIN2+ progression was due to the increased cervicovaginal diversity at V2 (p = 0.040). A full multivariate model of key components of the CVM showed significant protective effects via V1 genus Lactobacillus, OR = 0.41 (0.22-0.79), V1 fungal diversity, OR = 0.90 (0.82-1.00) and V1 functional Cell Motility pathway, OR = 0.75 (0.62-0.92), whereas V2 bacterial diversity, OR = 1.19 (1.03-1.38) was shown to be predictive of progression to CIN2+.

conclusionThis study demonstrates that features of the cervicovaginal microbiome are associated with HR-HPV progression in a prospective longitudinal cohort. The analyses indicated that the association of Gardnerella and progression to CIN2+ may actually be mediated by subsequent elevation of microbial diversity. Identified features of the microbiome associated with HR-HPV progression may be targets for therapeutic manipulation to prevent CIN2+.

trial registrationClinicalTrials.gov NCT00128661.

Indexed as

Cervix UteriGardnerellaLactobacillusMicrobiotaPapillomavirus InfectionsUterine Cervical DysplasiaUterine Cervical NeoplasmsVaginaAdolescentAdultFemaleHumansLongitudinal StudiesPapillomaviridae

Identifiers

PMID32214382
PMCPMC7098574
OpenAlexW3013498851

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.